Cel-Sci Corporation (CVM) Covered Calls

You can sell covered calls on Cel-Sci Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CVM (prices last updated Tue 4:16 PM ET):

Cel-Sci Corporation (CVM) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
1.11 -0.14 1.10 1.15 729K - 0.1
Covered Calls For Cel-Sci Corporation (CVM)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Jun 21 1 0.00 1.15 -13.0% -1186.2%
Jul 19 1 0.00 1.15 -13.0% -148.3%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.